Also known as cjc/ipa, cjc/ipa blend, cjc/ipam combo, mod-grf + ipamorelin, cjc & ipa
CJC-1295 + Ipamorelin is a pre-mixed research-chemical blend of two growth-hormone secretagogues that act on parallel pituitary pathways. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) that binds the pituitary GHRH receptor; vendors sell either a "no-DAC" form (also called mod-GRF 1-29, plasma t1/2 ~30 min) or a "DAC" form bearing a maleimido-propionic-acid albumin-binding tether (plasma t1/2 ~6-8 days). Ipamorelin is a selective pentapeptide agonist of the ghrelin/GHS-R1a receptor. The blend exploits the long-standing endocrine observation that combining a GHRH analog with a ghrelin-receptor agonist produces a markedly larger GH pulse than either drug alone. It is widely sold in the United States as a research chemical but is not approved for human therapeutic use; users should confirm whether the CJC component is DAC or no-DAC before dosing.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Formulation note
'CJC-1295' in blend SKU names typically refers to the no-DAC (Mod-GRF 1-29) short-acting version, not the long-acting DAC variant. Verify per vendor — long-acting CJC-1295-DAC + ipamorelin is mechanistically very different (continuous vs pulsatile GH release).
What's in this blend
Growth
CJC-1295 without DAC, also called Mod-GRF(1-29) or tetrasubstituted GRF(1-29), is a short-acting growth hormone-releasing hormone analog built from the first 29 amino acids of native human GHRH with four amino-acid substitutions that resist DPP-IV cleavage.
Growth
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a selective ghrelin/GHSR1a receptor agonist.
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
CJC-1295 binds the pituitary somatotroph GHRH receptor, a class-B GPCR, raising intracellular cAMP and increasing the amplitude of pulsatile GH secretion; the DAC variant's albumin tether extends its plasma half-life to ~6-8 days and produces sustained 2-10x baseline GH and 1.5-3x baseline IGF-1 elevations in healthy adults (Teichman et al.
Pharmacokinetic properties
Half-life
No-DAC CJC-1295 (mod-GRF 1-29): ~30 min plasma. DAC CJC-1295: ~5.8-8.1 days (Teichman 2006). Ipamorelin: ~2 h plasma.
Routes
subcutaneous
Bioavailability
Both peptides are administered subcutaneously; not orally bioavailable. Blended vials commonly contain CJC and ipamorelin in a 1:1 to 2:1 ratio by mg. Whether the CJC is DAC or no-DAC dramatically changes appropriate dosing frequency - DAC is typically dosed 1-2x weekly, no-DAC 1-3x daily. Vendors do not always specify which form is present.
Amino-acid sequence
CJC-1295 (DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Lys-Cys-NH2 with N-terminal maleimido-propionic-acid linker for albumin conjugation. Mod-GRF 1-29 / no-DAC CJC-1295: same first 29-residue backbone without the DAC linker. Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 aa pentapeptide amide).
Use & research dosing
Research framing only. The most commonly reported community protocol pairs roughly 100 mcg of no-DAC CJC-1295 (mod-GRF 1-29) with 100-200 mcg of ipamorelin per subcutaneous injection, dosed 1-3 times daily - typically immediately before bed to align with the natural nocturnal GH pulse and additional pre- and post-workout doses - run in 8-12 week cycles separated by off-periods. DAC-form CJC-1295 has fundamentally different kinetics and is typically dosed at approximately 1-2 mg subcutaneously once or twice weekly because of its multi-day plasma half-life. No human dose-finding study exists for the blended commercial product; the only published clinical pharmacokinetic data come from separate Phase I trials of each individual component, and there is no trial of any commercial CJC-1295 plus ipamorelin combination.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
CJC-1295 + ipamorelin is the single most popular GH-secretagogue blend in the research and longevity community. The mechanistic rationale (parallel GHRH-receptor and ghrelin-receptor activation) is well-grounded in classical neuroendocrinology, and short-term human data exist for the individual components. However, no human trial has tested the specific commercial blend, long-term safety is unknown, and the vendor market is characterized by inconsistent labelling of DAC vs no-DAC CJC. Clinical development of CJC-1295 (DAC) was halted in the late 2000s and has not resumed; ipamorelin development was likewise discontinued. Users should not conflate "well-studied components" with "well-studied product."
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
medium
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.